Print PDF

Sheppard Mullin Represents Decoy Biosystems In Definitive Merger Agreement With Intec Pharma


Sheppard, Mullin, Richter & Hampton LLP represented Decoy Biosystems, Inc., a privately held, preclinical-stage biotechnology company developing novel, multi-targeted products that safely prime both innate and adaptive anti-tumor and anti-viral immune responses, in connection with its definitive merger agreement with Intec Pharma Ltd. (NASDAQ: NTEC), a clinical-stage biopharmaceutical company. The combined company will advance its immunotherapy platform to battle a variety of tumor types and chronic viral infections. The merger is expected to close in the third quarter of 2021.

The Sheppard Mullin deal team, led by partners Michael Umansky and Jamie Mercer, included special counsel Jeff Gardner and associates Alex Yarbrough and Andrea Ramos.

Click here to read the press release.


Jump to Page

By scrolling this page, clicking a link or continuing to browse our website, you consent to our use of cookies as described in our Cookie and Advertising Policy. If you do not wish to accept cookies from our website, or would like to stop cookies being stored on your device in the future, you can find out more and adjust your preferences here.